Login to Your Account



Safety Profile Clean

Apremilast Nails Primary Endpoint in Psoriasis Phase III

By Catherine Shaffer
Staff Writer

Tuesday, March 5, 2013
Celgene Corp. presented detailed results from its ESTEEM 1 Phase III trial of apremilast for psoriasis at the annual meeting of the American Academy of Dermatology in Miami. The trial met the threshold for statistical significance for its primary endpoint of 75 percent improvement in psoriasis area and severity index (PASI-75) at week 16 compared to placebo.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription